Liv Pure Peptide Product: Selank

Liv Pure Peptides Selank (Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro) Category: Cognitive Support $49.99 CAS# 129954-34-3 Formula: C33H57N11O9 Molecular Weight: 751.900 g/mol

Selank is a synthetic peptide analogue of tuftsin, developed for research exploring its neuromodulatory effects. Investigators have noted its potential to reduce anxiety while enhancing memory and learning processes. Additionally, preclinical studies suggest that Selank may modulate pain perception, making it a compelling subject for examining neuroprotective and cognitive support mechanisms.

This peptide is provided for research applications only and is intended solely for laboratory experimentation.

For Research Use Only – Not for Human Consumption.

Sizes

View COA: 0202266

At Liv Pure Peptides, innovation meets purity. Our advanced research and rigorous quality standards deliver breakthrough peptide solutions for better health and science.

Shop Products

Products

Pages

Legal

Newsletter Signup

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

All products provided by Liv Pure are intended solely for in‑vitro laboratory research purposes. These materials are expressly forbidden for any form of human or animal use, ingestion, or administration, and all products are sold strictly for research, laboratory, or analytical purposes – not for human consumption.

The products offered on this platform are not formulated, designed, or intended to diagnose, cure, mitigate, treat, or prevent any diseases or medical conditions. Additionally, these statements have not been evaluated by the Food and Drug Administration, and our products are not intended to diagnose, treat, cure, or prevent any disease.

All products are for Research and Development use only and are not for human consumption.

Liv Pure is a chemical supplier; LIV Pure Peptides is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor is it an outsourcing facility as defined under Section 503B of the Act.